Trastuzumab

Trastuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ERBB2 (HER2 , Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD/antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2, NGL), for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Trastuzumab is a humanized monoclonal antibody for patients with invasive breast cancers that overexpress HER2. Trastuzumab has the potential for HER2 Positive Metastatic Breast Cancer and HER2 Positive Gastric Cancer research.

Target	ERBB2 (HER2 , Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD/antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2, NGL)
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	180288-69-1
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on ERBB2 (HER2 , Tyrosine kinase-type cell surface receptor HER2, MLN19, Metastatic lymph node gene 19 protein, ERBB2, Proto-oncogene Neu, p185erbB2, CD/antigen=CD340, Proto-oncogene c-ErbB-2, MLN 19, NEU, Receptor tyrosine-protein kinase erbB-2, NGL)

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue